Abstract: The present disclosure is concerned with ?-carboline adducts and dimer compounds comprising two ?-carboline moieties and methods of synthesizing the same. The methods described herein may also be used to synthesize a wide array of ?-carboline adducts and dimer compounds, depending upon the reactants used. Generally, the method comprises reacting a tryptamine and an acid chloride or diacid chloride in acetonitrile to yield harmaline compounds which can be easily converted to harmine or tetrahydroharmine if desired.

Abstract: Fused tricyclic compounds and novel methods of synthesizing, using, and/or administering the same. Methods of inhibiting microbial activity and/or treating a microbial infection with fused tricyclic compounds, bicyclic compounds, and other polycyclic compounds. The treatment of subjects suffering from a microbial infection comprises the step of administering to the subject one or more fused tricyclic compounds, bicyclic compounds, and other polycyclic compounds or a composition comprising one or more fused tricyclic compounds, bicyclic compounds, and other polycyclic compounds.

Abstract: Methods for the synthesis of harmine comprise reacting harmaline with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in the presence of a diacid catalyst. In an embodiment, the synthesis is carried out using a reaction mixture of harmaline, DDQ, THF solvent, and succinic acid; the reaction is carried out under an inert atmosphere with refluxing for a period of 4-12 hours.

Abstract: The treatment of human subjects suffering from COVID-19 comprises the step of administering to the human subjects a medicament selected from the group consisting of 1,3-bis(7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propane, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts thereof. The medicament may also be contacted with SARS-CoV-2 virus for inhibition of the virus.

Abstract: The treatment of human subjects suffering from COVID-19 comprises the step of administering to the human subjects a medicament selected from the group consisting of 1,3-bis(7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propane, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts thereof. The medicament may also be contacted with SARS-CoV-2 virus for inhibition of the virus.

Abstract: Low-temperature syntheses of thymoquinone/harmaline compounds which are useful for the treatment of human diabetes and cancers, and the derivatives, solvates, prodrugs, isomers, and tautomers of such compounds.

Abstract: Methods for the synthesis of harmine comprise reacting harmaline with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in the presence of a diacid catalyst. In an embodiment, the synthesis is carried out using a reaction mixture of harmaline, DDQ, THF solvent, and succinic acid; the reaction is carried out under an inert atmosphere with refluxing for a period of 4-12 hours.